Warburg Pincus-led investor group acquires PANTHERx Rare
The sale of the nation's largest independent rare pharmacy, based in Pittsburgh, sees Nautic Partners, General Atlantic, and The Vistria Group exit, with Nautic and management retaining significant stakes.
Takeaways
- PANTHERx Rare is a rare disease pharmacy and patient care platform.
- Warburg Pincus and PANTHERx Rare are classified as a platform transaction.
- The target serves rare disease patients and pharmaceutical partners across Pittsburgh, PA.
PANTHERx Rare, the largest independent rare pharmacy in the U.S. and a pioneer in the rare disease pharmacy model, has been acquired by a Warburg Pincus-led investor group from Nautic Partners, General Atlantic, and The Vistria Group.
The Pittsburgh-based company is licensed in all 50 states and was the first national pharmacy to achieve dual accreditations in rare disease from ACHC and URAC.
Nautic Partners and PANTHERx management will remain significant shareholders, while General Atlantic and The Vistria Group exit.
“When we invested in PANTHERx, we saw a company with the unique potential to redefine the specialty pharmacy model for rare diseases,” said Mo Yang, Partner at The Vistria Group.
The transaction is expected to close in the coming months, subject to customary closing conditions and regulatory approvals.
Morgan Securities LLC served as financial advisor and Cleary Gottlieb served as legal counsel to Warburg Pincus.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.